Intellectual Property Waiver for Vaccines - VISION

Material For Exam

Recent Update

Saturday, May 08, 2021

Intellectual Property Waiver for Vaccines

 Why in news?

Recently, U.S. government has said that it will support for the waiving Intellectual Property (IP) protection for Covid-19 vaccines.

What are Patents?

  • A patent represents a powerful IP right and is an exclusive monopoly granted by a government to an inventor for a limited, pre-specified time.
  • It provides an enforceable legal right to prevent others from copying the invention.
  • Patents can be either process patents or product patents.
  • A product patent ensures that the rights to the final product is protected and anyone other than the patent holder is restrained from manufacturing it during a specified period.
  • This is applicable even in the cases if they were to use a different process.
  • A process patent enables any person other than the patent holder to manufacture the patented product by modifying certain processes in the manufacturing exercise.

What does India follow?

  • India moved from product patenting to process patenting in the 1970s, which enabled India to become a significant producer of generic drugs at global scale.
  • Between 1972 and 2005, India had adopted process patenting rather than product patenting, and built up a huge generic industry.
  • This allowed companies like Cipla to provide Africa with anti-HIV drugs in the 1990s.
  • But due to obligations arising out of the TRIPS Agreement, India had to amend the Patents Act in 2005 and switch to a product patents regime across the pharma, chemicals, and biotech sectors.

What was the earlier proposal from India and South Africa?

  • In October 2020, India and South Africa had asked the WTO to waive certain conditions of the TRIPS Agreement.
  • This was related to the provisions in TRIPS that could impede timely access to affordable medical products to combat Covid-19 which includes – testing, diagnostics and novel therapeutics.
  • They also asked for enforcement of four sections -1, 4, 5, and 7 -in the second part of the agreement which pertain to copyright and related rights, industrial designs, patents etc.
  • The proposal said that developing countries are facing institutional and legal difficulties when using flexibilities available in the TRIPS Agreement.

What does IP waiver for Covid-19 vaccines mean?

  • It will result in the production of Covid vaccines with emergency use authorisations (EUA) on a larger scale in middle-income countries.
  • Currently most of the production is concentrated in high-income countries and production in the middle-income countries   happens through licensing or technology transfer agreements.
  • But the pharmaceutical companies say that ramping up the production capacities and it will take at least a few months.

What are the deterrents for the waiver?

  • Earlier pharma companies opposed the proposed waiver saying that eliminating IP protections would undermine global response to the pandemic, including the ongoing efforts to tackle new variants.
  • It could create confusion that could potentially undermine public confidence in vaccine safety and create a barrier to information sharing.
  • They say that it would not be feasible for a company to move vaccines to a developing nation as these countries do not have the capacity to speedily produce vaccines.

What are the other roadblocks to scaling up production?

  • The real challenges include trade barriers, bottlenecks in supply chains, scarcity of raw materials and ingredients in the supply chain & unwillingness of rich countries to share doses with poorer nations.
  • The scarcity of raw materials has been a growing issue for ramping up production, several manufacturers have been relying on specific suppliers and alternatives are limited.
  • Also, countries like the US had blocked exports of critical raw materials used in the production of some Covid-19 vaccines using regulations like the American Defence Production Act (DPA).
  • This led to a delay in the production of Covid vaccines by some companies in India.
  • In India, vaccine manufacturers said that the use of the DPA had blocked exports of plastic bags, filters and certain media used in the production of the version of Novavax vaccine.

 

Source: The Indian Express